AGENUS INC

AGEN

Explore Our Financial Data > Companies > AGENUS INC

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AGEN
CIK	0001098972
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	3 FORBES ROAD, LEXINGTON, MA, 02421
Website	agenusbio.com
Phone	781-674-4410
CEO	Garo H. Armen
Employees	440

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$106.83 million
Pre-Tax Income	$-119.30 million
Net Income	$-39.28 million
Net Income to Common	$-35.38 million
EPS	$-1.11

View All

Balance Sheet

Cash	$3.46 million
Assets	$233.89 million
Liabilities	$514.76 million
Common Equity	$-274.14 million
Liabilities & Equity	$233.89 million

View All

Cash Flow Statement

Net Income	$-39.28 million
Cash From Operating Activities	$-89.23 million
Cash From Investing Activities	$393,000.00
Cash From Financing Activities	$45.59 million
Change in Cash	$-43.25 million

View All

Calculations

NOPAT	$-42.32 million
EBITDA	$-47.80 million
Price to Earnings	N/A
Price to Book	N/A
ROE	14.21%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight

The colorectal cancer market is growing due to rising incidence driven by aging populations and lifestyle risk factors, which increases demand for screening and treatment. Advances in molecular diagnostics, targeted therapies, and immuno-oncology agents are expanding treatment options and prolonging patient survival. Additionally, the launch of emerging therapies such as Serplulimab (HLX10) + Bevacizumab + Chemotherapy (Shanghai Henlius Biotech), Botensilimab ± Balstilimab (Agenus), TTX-080 (Tiz

Article Link

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

LEXINGTON, Mass., November 19, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer.

Article Link

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

LEXINGTON, Mass., November 18, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel

Article Link

LGND: Target Up On Improved Growth Outlook

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third quarter, with revenues almost double our estimates and adjusted core earnings per share (EPS) more than 60% greater. While contributions from the spin out of Pelthos contributed the most, revenue growth in other areas was also strong.

Article Link

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link